Nevirapine
- Generic Name
- Nevirapine
- Brand Names
- Viramune
- Drug Type
- Small Molecule
- Chemical Formula
- C15H14N4O
- CAS Number
- 129618-40-2
- Unique Ingredient Identifier
- 99DK7FVK1H
- Background
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
- Indication
For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Preventing Sexual Transmission of HIV With Anti-HIV Drugs
- First Posted Date
- 2003-12-17
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 3526
- Registration Number
- NCT00074581
- Locations
- 🇺🇸
Fenway Community Health Ctr. CRS, Boston, Massachusetts, United States
🇧🇼Gaborone CRS, Gaborone, Botswana
🇧🇷Hospital Geral de Nova Iguaçu CRS (HGNI CRS), Nova Iguacu, Rio De Janeiro, Brazil
Nevirapine (NVP) Use to Prevent Mother-to-Child Transmission of HIV
- First Posted Date
- 2003-12-15
- Last Posted Date
- 2009-08-07
- Target Recruit Count
- 775
- Registration Number
- NCT00074399
- Locations
- 🇪🇹
Tikur Anbessa Hospital, Addis Ababa, Ethiopia
Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding
- First Posted Date
- 2003-12-15
- Last Posted Date
- 2023-02-16
- Target Recruit Count
- 2026
- Registration Number
- NCT00074412
- Locations
- 🇿🇼
Seke North CRS, Chitungwiza, Zimbabwe
🇹🇿Muhimbili University of Health and Allied Sciences (MUHAS) CRS, Dar es Salaam, Tanzania
🇿🇼St Mary's CRS, Chitungwiza, Zimbabwe
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: TAF w/cobicistat or ritonavirDrug: tenofovir alafenamide fumarate (TAF)Drug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: fosamprenavir/ritonavirDrug: atazanavir/ritonavir dosage #1Drug: didanosine delayed release (Videx® EC)Drug: emtricitabineDrug: nelfinavir dosage #1Drug: tipranavir/ritonavirDrug: etravirineDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: rilpivirineDrug: ethambutolDrug: efavirenzDrug: raltegravirDrug: dolutegravirDrug: kanamycinDrug: nevirapineDrug: amprenavirDrug: abacavirDrug: tenofovirDrug: maravirocDrug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: nelfinavir dosage #2Drug: rifampicinDrug: amikacinDrug: darunavir/ritonavir dosage #3Drug: etonogestrel implantDrug: capreomycinDrug: ethinyl estradiolDrug: isoniazidDrug: moxifloxacinDrug: levoflaxacinDrug: pyrazinamideDrug: ofloxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)Drug: high dose INHDrug: bedaquilineDrug: clofazamineDrug: delamanidDrug: linezolidDrug: pretomanid
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine
- Conditions
- First Posted Date
- 2002-05-22
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00001688
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients
- Conditions
- First Posted Date
- 2001-12-21
- Last Posted Date
- 2013-07-29
- Target Recruit Count
- 150
- Registration Number
- NCT00028314
- Locations
- 🇺🇸
Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸Washington U CRS, St. Louis, Missouri, United States
🇺🇸Univ. of Texas Medical Branch, ACTU, Galveston, Texas, United States
The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-04
- Target Recruit Count
- 30
- Registration Number
- NCT00000962
- Locations
- 🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States
🇺🇸Univ of Minnesota, Minneapolis, Minnesota, United States
Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 3720
- Registration Number
- NCT00021671
- Locations
- 🇺🇸
Megan Valentine, Research Triangle Park, North Carolina, United States
A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 390
- Registration Number
- NCT00000814
- Locations
- 🇺🇸
Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States
🇺🇸Saint Christopher's Hosp for Children, Philadelphia, Pennsylvania, United States
🇺🇸Emory Univ Hosp / Pediatrics, Atlanta, Georgia, United States
Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 55
- Registration Number
- NCT00000872
- Locations
- 🇺🇸
Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States
🇺🇸Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States
🇺🇸BMC, Div. of Ped Infectious Diseases, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.